Cogent Biosciences, Inc. (COGT) Financial Statements
Cogent Biosciences, Inc. (COGT) reported trailing twelve-month revenue of $7.9M (up 4637.4% year on year) and net income of -$377.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$309.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
COGTCogent Biosciences, Inc.Follow COGT — free
—
Price chart with a free account
- Market cap
- 5.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 16 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 38.3 | 43.7 | 25.7 | 55.9 | 121.6 | 173.8 | 232.7 | 269.8 | 290.7 | |
| Operating income | -36.0 | -32.2 | -82.2 | -75.6 | -147.8 | -208.1 | -275.9 | -333.4 | -389.1 | |
| Pre-tax income | -34.5 | -31.8 | -74.8 | -72.3 | -140.2 | -192.4 | -255.9 | -328.9 | -377.2 | |
| Income tax | — | — | — | — | — | — | — | 0.0 | — | |
| Net income | -34.5 | -31.8 | -74.8 | -72.3 | -140.2 | -192.4 | -255.9 | -328.9 | -377.2 | |
| Diluted EPS ($) | -1.39 | -4.18 | -16.17 | -1.87 | -1.73 | -1.94 | -1.94 | -2.16 | -1.95 | |
| Diluted shares (mn) | — | — | — | — | 58.7 | 79.7 | 103.9 | 128.9 | — |
USD millions · SEC XBRL
Cogent Biosciences, Inc. — questions
- What is Cogent Biosciences, Inc.'s revenue?
- $7.9M over the twelve months to 2026-06-30, up 4637.4% year on year, from its 10-Q and 10-K filings.
- What is Cogent Biosciences, Inc.'s net income?
- -$377.2M over the twelve months to 2026-06-30.
- What is Cogent Biosciences, Inc.'s free cash flow?
- -$309.2M over the twelve months to 2026-06-30.
- What are Cogent Biosciences, Inc.'s diluted earnings per share?
- $-1.95 over the twelve months to 2026-06-30.
Every figure on this page comes from Cogent Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.